Dr Martens Q3 Sales Dip 3.1% to £253M, Profit Growth Intact
Dr Martens PLC's Q3 revenues fell 3.1% to £253 million, a steeper decline than the 0.8% drop in H1. The bootmaker maintained its forecast for significant profit growth in the current financial year despite slower sales momentum.
1. Intraday Pullback in Shares
Shares of Doximity experienced a notable pullback during the most recent trading session, falling by 3.56% from the prior close on volume that was approximately 25% above the 30-day average. Analysts point to short-term profit taking following a six-day rally that lifted the stock more than 12%. Institutional ownership remains high at 72%, suggesting that longer-term holders are largely undeterred by the recent dip.
2. Zacks Upgrades to Strong Buy on Earnings Upside
Doximity received an upgrade to a Zacks Rank #1 (Strong Buy) after consensus earnings estimates for the upcoming quarter were raised by 20%, from $0.12 per share to $0.15. The revision reflects growing optimism around the company’s telehealth platform adoption and higher average revenue per user, which has risen 8% year-over-year. Zacks analysts now project full-year revenue growth of 32%, up from 28% prior to the upgrade.